logo
Hypervolemia (Fluid Overload) Symptoms, Causes, and Treatment

Hypervolemia (Fluid Overload) Symptoms, Causes, and Treatment

Health Line02-06-2025
Hypervolemia occurs if your body retains too much fluid. You can experience swelling, discomfort, and other symptoms. Untreated, hypervolemia can cause severe complications, including heart failure.
Hypervolemia, or fluid overload, occurs when your body holds onto more fluid than it needs, leading to swelling and other complications.
Fluids in the body include:
water
blood
lymphatic fluid
If the amount of fluid gets too high, it can impact how it's moved through your body and negatively affect your organ function.
Keep reading to learn the signs and causes of hypervolemia and how doctors diagnose and treat the condition.
What are the signs and symptoms of hypervolemia?
The symptoms of hypervolemia can include:
swelling, also called edema, most often in the feet, ankles, wrists, and face
discomfort in the body, causing cramping, headache, and abdominal bloating
high blood pressure caused by excess fluid in the bloodstream
shortness of breath caused by extra fluid entering your lungs and reducing your ability to breathe normally
heart problems, because excess fluid can speed up or slow your heart rate, harm your heart muscles, and increase the size of your heart
increased weight, caused by excess fluid
Medical emergency
If you experience severe symptoms, such as difficulty breathing, severe pain, or irregular heart rhythm, call 911 or your local emergency services, or visit a local emergency department.
What causes hypervolemia?
Often, problems with your kidneys cause hypervolemia. This is because the kidneys normally balance the salts and fluids in your body.
But when they retain salt, they increase the body's total sodium content, which increases your fluid content.
The most common causes of hypervolemia can include:
heart failure, specifically of the right ventricle
cirrhosis, often caused by excess alcohol consumption or hepatitis
kidney failure, often caused by diabetes and other metabolic disorders
nephrotic syndrome, a disorder that causes excess excretion of protein in the urine
premenstrual edema, or swelling that occurs prior to your menstrual cycle
pregnancy, which changes your hormonal balance and can result in fluid retention
You can also experience hypervolemia from being on an IV, which can cause your sodium levels to be unbalanced. It can also occur if you consume too much sodium.
How is hypervolemia diagnosed?
If you believe you're experiencing hypervolemia, speak with a doctor. They can determine if you're experiencing this condition.
First, a doctor typically conducts a physical exam. The key signs of hypervolemia include weight gain and swelling. One or more parts of your body may appear swollen, depending on whether you have been sitting, lying, or standing before your visit.
The doctor is also likely to perform a blood test to check your sodium levels. While your body's total sodium levels will appear elevated if you have hypervolemia, your sodium levels in the blood work may be high, normal, or low.
Performing a sodium test on your urine can help determine if your kidneys are causing your hypervolemia or if there is another cause.
For renal failure, urinary sodium content is typically greater than 20 milliequivalents per liter (mEq/L), while in cases of heart failure, cirrhosis, and nephrotic syndrome, it is typically less than 10 mEq/L.
If you are hospitalized, your care team may measure your fluid intake and output and your weight to check for hypervolemia.
Can hypervolemia lead to other conditions?
Untreated hypervolemia can cause several complications, some of which can be life threatening. These can include:
pericarditis, or swelling of the heart tissues
heart failure
delayed wound healing
tissue breakdown
decreased bowel function
How is hypervolemia treated?
Treatment of hypervolemia differs from person to person, depending on the cause of the condition.
Generally, people with hypervolemia may receive a round of diuretics. These medications remove excess fluid.
In severe cases, a doctor may recommend dialysis (fluid removal through the kidneys) and paracentesis (fluid removal through the abdomen).
A doctor may also require you to restrict your dietary sodium intake.
What is the outlook for hypervolemia?
While you recover from hypervolemia, a doctor may request that you weigh yourself daily to ensure you're expelling the excess fluid from your body.
Many people who stick to a doctor's treatment plans fully recover. This can be important for preventing severe complications.
If an underlying condition is causing your hypervolemia, treating the underlying condition may help your recovery.
Besides monitoring your weight, you can prevent a recurrence of fluid overload by:
tracking your fluid intake
following the fluid intake guidelines from a doctor
managing your thirst with sugar-free candies, ice chips, frozen grapes, and other low-fluid, thirst-quenching foods
ensuring you do not consume too much sodium
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns

Yahoo

time3 hours ago

  • Yahoo

Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns

Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store